Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Weintraub, J. Koester, M. Potenza, A. Siderowf, M. Stacy, V. Voon, Jacqueline Whetteckey, Glen Wunderlich, A. Lang (2010)
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.Archives of neurology, 67 5
L. Vroonen, A. Daly, A. Beckers (2019)
Epidemiology and Management Challenges in ProlactinomasNeuroendocrinology, 109
Bernardo 'osso, Ae Carlo, Altamura Ae, A. Allen, Ae Donatella, Marazziti Ae, E. Hollander (2006)
Epidemiologic and clinical updates on impulse control disorders: a critical reviewEuropean Archives of Psychiatry and Clinical Neuroscience, 256
American Psychiatric Association (2013)
10.1176/appi.books.9780890425596
Hayley MacDonald, C. Stinear, April Ren, J. Coxon, Justin Kao, L. Macdonald, B. Snow, S. Cramer, W. Byblow (2016)
Dopamine Gene Profiling to Predict Impulse Control and Effects of Dopamine Agonist RopiniroleJournal of Cognitive Neuroscience, 28
I. Bancos, Michael Nannenga, J. Bostwick, M. Silber, D. Erickson, T. Nippoldt (2014)
Impulse control disorders in patients with dopamine agonist‐treated prolactinomas and nonfunctioning pituitary adenomas: a case–control studyClinical Endocrinology, 80
S. Doğanşen, U. Cikrikcili, G. Oruk, N. Kutbay, S. Tanrikulu, Z. Hekimsoy, A. Hadzalic, S. Gorar, T. Omma, M. Mert, Gulhan Akbaba, G. Yalin, F. Bayram, M. Ozkan, S. Yarman (2019)
Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.The Journal of clinical endocrinology and metabolism, 104 7
M. Barake, A. Evins, L. Stoeckel, Gladys Pachas, L. Nachtigall, Karen Miller, B. Biller, N. Tritos, A. Klibanski (2014)
Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot studyPituitary, 17
JC Corvol (2018)
10.1212/WNL.0000000000005816Neurology, 91
S. Sousa, I. Chapman, H. Falhammar, D. Torpy (2017)
Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonistsEndocrine, 55
AG Ioachimescu (2019)
10.1530/EJE-18-0682Eur J Endocrinol, 180
V Voon (2009)
10.1016/S1474-4422(09)70287-XLancet Neurol, 8
Emir Celik, H. Ozkaya, B. Poyraz, Tarık Sağlam, P. Kadıoğlu (2018)
Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-upEndocrine, 62
CT Lim (2018)
10.4158/EP-2018-0034Endocr Pract, 24
H. Ozkaya, S. Şahin, Ozge Korkmaz, E. Durcan, H. Sahin, B. Poyraz, P. Kadıoğlu (2020)
MON-293 The Prevalence of Impulse Control Disorders in Patients with Acromegaly and Prolactinomas Treated with Dopamine AgonistsJournal of the Endocrine Society, 4
P. Seeman (2015)
Parkinson's disease treatment may cause impulse–control disorder via dopamine D3 receptorsSynapse, 69
M. Viana, L. Andrade (2012)
Lifetime Prevalence, age and gender distribution and age-of-onset of psychiatric disorders in the São Paulo Metropolitan Area, Brazil: results from the São Paulo Megacity Mental Health Survey.Revista brasileira de psiquiatria, 34 3
M. Grall-Bronnec, C. Victorri-Vigneau, Y. Donnio, J. Leboucher, M. Rousselet, E. Thiabaud, Nicolas Zreika, P. Derkinderen, G. Challet-Bouju (2017)
Dopamine Agonists and Impulse Control Disorders: A Complex AssociationDrug Safety, 41
J Martinkova (2011)
10.1097/WNF.0b013e3182281b2fClin Neuropharmacol, 34
J. Hinojosa-Amaya, N. Johnson, Christina González-Torres, E. Varlamov, C. Yedinak, S. McCartney, M. Fleseriu (2020)
Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary AdenomasFrontiers in Endocrinology, 11
N. Ben-Jonathan, R. Hnasko (2001)
Dopamine as a prolactin (PRL) inhibitor.Endocrine reviews, 22 6
J. Ahlskog (2011)
Pathological behaviors provoked by dopamine agonist therapy of Parkinson's diseasePhysiology & Behavior, 104
M Grall-Bronnec (2016)
10.1097/JCP.0000000000000444Rev J Clin Psychopharmacol, 36
Y. Greenman (2019)
Prolactinomas and menopause: any changes in management?Pituitary, 23
D. Weintraub, M. Nirenberg (2012)
Impulse Control and Related Disorders in Parkinson’s DiseaseNeurodegenerative Diseases, 11
V Voon (2017)
10.1016/S1474-4422(17)30004-2Lancet Neurol, 16
C. Vriend (2018)
The neurobiology of impulse control disorders in Parkinson’s disease: from neurotransmitters to neural networksCell and Tissue Research, 373
Janet Williams (2013)
Diagnostic and Statistical Manual of Mental Disorders
[Dopamine agonists (DA) are widely used in the management of prolactinomas, as they are largely effective in controlling tumor secretion and growth. Dopamine agonist administration is safe with only minor adverse effects reported in most cases (e.g., gastrointestinal symptoms and postural hypotension). Neuropsychiatric side effects such as impulse control disorders (ICD; e.g., pathological gambling, compulsive shopping, and hypersexuality) have been described in neurological patients treated for Parkinson’s disease and restless leg syndrome with high doses of DA. Accumulating evidence suggests that ICD in patients with prolactinomas treated with DA are not as rare as previously thought.]
Published: Jan 4, 2022
Keywords: Dopamine agonist; Treatment; Prolactinoma; Adverse effect; Impulse control disorder; Depression
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.